Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29755179 | 1.00 | GPR3 (0.30) | GPR3 | |
| SCHEMBL30991184 | 1.00 | GPR3 (0.30) | GPR3 | |
| SCHEMBL30810442 | 1.00 | GPR3 (0.30) | GPR3 | |
| SCHEMBL21132423 | 1.00 | GPR3 (0.30) | GPR3 | |
| SCHEMBL23526276 | 1.00 | GPR3 (0.30) | GPR3 | |
| SCHEMBL23526157 | 1.00 | GPR3 (0.30) | GPR3 | |
| SCHEMBL23526160 | 1.00 | GPR3 (0.30) | GPR3 | |
| SCHEMBL25130537 | 1.00 | GPR3 (0.30) | GPR3 | |
| SCHEMBL21132424 | 1.00 | GPR3 (0.30) | GPR3 | |
| SCHEMBL29863679 | 1.00 | GPR3 (0.30) | GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2023098825-A1 | SOS1 INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 勤浩医药（苏州）有限公司 | 2023-06-08 | — | — | WO | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023029833-A1 | SOS1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | GPR3 3611/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | GPR3 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.